Premium
Multimodality molecular imaging of the lung
Author(s) -
Chen Delphine L.,
Kinahan Paul E.
Publication year - 2010
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.22385
Subject(s) - positron emission tomography , multimodality , molecular imaging , magnetic resonance imaging , medicine , radiology , single photon emission computed tomography , functional imaging , preclinical imaging , medical imaging , medical physics , nuclear medicine , computer science , microbiology and biotechnology , biology , world wide web , in vivo
Abstract The continued progression of chronic lung disease despite current treatment options has led to the increasing evaluation of molecular imaging tools for diagnosis, treatment planning, drug discovery, and therapy monitoring. Concurrently the development of multimodality positron emission tomography (PET) / computed tomography (CT), single‐photon emission computed tomography (SPECT)/CT, and magnetic resonance imaging (MRI)/PET scanners has opened the potential for more sophisticated imaging biomarker probes. Here we review the potential uses of multimodality imaging tools, the established uses of molecular imaging in nononcologic lung pathophysiology and drug discovery, and some of the technical challenges in multimodality molecular imaging of the lung. J. Magn. Reson. Imaging 2010;32:1409–1420. © 2010 Wiley‐Liss, Inc.